UPB - Upstream Bio, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$15.00
DETAILS
HIGH:
$15.00
LOW:
$15.00
MEDIAN:
$15.00
CONSENSUS:
$15.00
UPSIDE:
87.97%
About Upstream Bio, Inc. (https://upstreambio.com)
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| E. Rand Sutherland | Chief Executive Officer & Director | 1970 | $1,001,750 USD |
| Aaron Deykin | Chief Medical Officer and Head of Research & Development | 1967 | $741,800 USD |
| Michael Paul Gray | Chief Financial Officer & Chief Operating Officer | 1971 | $706,300 USD |
| Allison Ambrose | Senior Vice President, General Counsel & Secretary | 1985 | $59,792 USD |
| Adam Houghton | Chief Business Officer | 1971 | – |
| Fang Xie | Vice President & Head of Biometrics | – | – |
| Lisa Fiering | Senior Vice President of People & Culture | – | – |
| Meggan Buckwell | Director of Corporate Communications & Investor Relations | – | – |
| Mersedeh Miraliakbari | Senior Vice President of Regulatory Affairs & Quality | – | – |
| Stacy Price | Chief Technology Officer | 1969 | – |